Mathew Aby J. 4

What Happened

• Mathew Aby, EVP & Chief Scientific Officer of BioLife Solutions (BLFS), received restricted stock awards on Feb 24, 2026 totaling 59,701 shares (20,096 shares and 39,605 shares). To cover tax withholding on vesting, 15,585 shares were withheld/disposed at $22.65 each, totaling about $353,000.
• These were compensation awards (not an open-market purchase or voluntary sale). One award is a time-based restricted stock grant tied to 2026 compensation and the other was a market-based award that vested at approximately 156% of the original grant based on relative total shareholder return.

Key Details

• Transaction date: 2026-02-24; Form 4 filed 2026-02-26 (timely within typical two-business-day window).
• Grants: 20,096 shares (time-based restricted stock) and 39,605 shares (market-based/performance restricted stock).
• Tax withholding: 15,585 shares withheld/disposed to satisfy tax obligations at $22.65/share, amounting to ~$353,000 (footnote indicates withholding relates to the vested market-based award).
• Plan: Awards granted under the BioLife Solutions 2023 Omnibus Performance Incentive Plan.
• Shares owned after the transaction: not specified in the provided filing.

Context

• This filing reflects compensation-related awards and routine tax withholding — common for vesting restricted stock — rather than a buy or a proactive sale signaling a trading decision.
• The market-based award’s payout level (≈156%) was determined by BioLife’s total shareholder return relative to peer companies for 1/1/24–12/31/25, per the filing.